- Patients with breast cancer who are single hormone receptor-positive (ER+PR− or ER−PR+) have worse DFS, breast cancer-specific survival (BCSS), OS, and recurrence than patients who are double-positive (ER+PR+).
Why this matters
- ER+PR− or ER−PR+ tumors may require more aggressive treatment than ER+PR+ tumors.
- Meta-analysis of 22 studies (n=217,485 women) after a search of Google Scholar and the Cochrane database.
- Most of the 22 studies were of stage I-III breast cancer.
- Funding: National Nature Science Foundation of China; others.
- Worse DFS (vs ER+PR+):
- ER+PR−: HR, 1.60; 95% CI, 1.44-1.77.
- ER−PR+: HR, 2.27; 95% CI, 1.67-3.09.
- Worse BCSS (vs ER+PR+):
- ER+PR−: HR, 1.43; 95% CI, 1.33-1.53.
- ER−PR+: HR, 1.82; 95% CI, 1.68-1.98.
- Worse OS (vs ER+PR+)
- ER+PR−: HR, 1.38; 95% CI, 1.28-1.47.
- ER−PR+: HR, 1.48; 95% CI, 1.17-1.89.
- Worse risk for recurrence in the following subgroups (ER+PR− vs ER+PR+):
- HER2− subgroup: HR, 1.57; 95% CI, 1.32-1.87.
- Lymph node-negative subgroup: HR, 2.03; 95% CI, 1.44-2.86.
- Endocrine therapy-positive subgroup: HR, 1.65; 95% CI, 1.45-1.89.
- Worse DFS in subgroup with HER2−/ER−PR+ (vs HER2−/ER+PR+): HR, 3.10; 95% CI, 1.92-5.10.
- Study design of individual studies not specified.